Capital investment data from Pitchbookan online platform for investment data, reveals a more or less consistent level of capital that has been invested in the fields of ALS, HD, and MG over the past 10 years (Figure ) while the number of deals shows a moderate increase during the same period. Interestingly, there is a mild decline in the amount of money invested in this field over the last 3 years (2021-2023) which could be indicative of a slight decrease in commercial interest but the exact reason for this remains unknown. In terms of the geographical distribution of capital investment in the field of rare diseases, the US led with respect to capital investment from 2013 to 2023, followed by Belgium, the Netherlands, and the UK (Figure ). The investment in the US is ∼14 times that of the next top contributor-Belgium and ∼27 times that of the Netherlands. Growth in the capital investment made from 2013-2023 for the few leading countries/regions shows a moderate overall increase till 2021, post which it shows a minor dip till 2023 (Figure ). Of note, the capital investment by Belgium and the UK has increased in the last 2 years (2021-2023). A closer look at the data suggests that life sciences-based industries are the top investors followed by oncology-based and health technology industries (Figure ). Vaccinex has the maximum number of deals in this field. Vaccinex lead drug candidate, pepinemab (CAS RN: 2097151-87-4), blocks semaphorin 4D (SEMA4D), a key driver of neuroinflammation. This drug has the potential as a disease-modifying treatment for HD, Alzheimer's, and other neurodegenerative diseases and is currently in Phase II clinical trials. Similarly, Cytokinetics is investing in diseases linked to neuromuscular junction such as ALS. Sangamo Therapeutics is working towards the preclinical development of a zinc finger transcriptional repressor targeting the SCN9A gene as a novel therapy for peripheral neuropathic pain which could be effective against ALS. These investment trends indicate the steady interest of companies in the field of rare diseases such as ALS, HD, and MG.